Pacira Biosciences Inc PCRX:NASDAQ

Last Price$43.66NASDAQ Previous Close - Last Trade as of 4:00PM ET 6/14/19

Today's Change0(0.00%)
Bid (Size)$43.66 (16)
Ask (Size)$43.67 (14)
Day Low / HighN/A - N/A
Volume401.6 K
 

View Pharmaceuticals: Other IndustryPeer Comparison as of 06/14/2019

 

Pacira Biosciences Inc ( NASDAQ )

Price: $43.66
Change: -0.42 (0.95%)
Volume: 401.6 K
4:00PM ET 6/14/2019
 
 

Portola Pharmaceuticals Inc ( NASDAQ )

Price: $25.79
Change: +0.04 (0.16%)
Volume: 598.9 K
3:59PM ET 6/14/2019
 
 

Zogenix Inc ( NASDAQ )

Price: $39.16
Change: +0.03 (0.08%)
Volume: 273.1 K
3:59PM ET 6/14/2019
 
 

Supernus Pharmaceuticals Inc ( NASDAQ )

Price: $31.41
Change: -0.69 (2.15%)
Volume: 313.6 K
4:00PM ET 6/14/2019
 
 

Ironwood Pharmaceuticals Inc ( NASDAQ )

Price: $10.37
Change: -0.60 (5.47%)
Volume: 733.0 K
4:00PM ET 6/14/2019
 

Read more news Recent News

Pacira Pharmaceuticals Says Data Show Its Pain Medication Cuts Opioid Use After Hip Surgery
8:13AM ET 6/12/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) reported that new data that show that patients receiving EXPAREL after hip replacement surgery had a reduction in opioid use,...

Analyst Actions: Barclays Initiates Coverage on Pacira Pharmaceuticals With Overweight Rating, $52 PT
11:37AM ET 6/11/2019 MT Newswires

Pacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $55. Price: 41.63, Change: -1.41, Percent Change:...

Pacira Pharmaceuticals Reports Efficacy & Safety of Treatment for Patients Undergoing Shoulder Arthroplasty
8:15AM ET 6/04/2019 MT Newswires

Pacira Pharmaceuticals (PCRX) said a multinational phase 3 study supported the efficacy and safety of exparel as a single-injection interscalene brachial...

Analysts Ratchet Up Expectations for Pacira Pharmaceuticals' Q2 and Full Year Earnings
7:26AM ET 5/11/2019 MT Newswires

Pacira Pharmaceuticals Inc's (NASDAQ:PCRX, Recent Price: 47.97) Q2 quarterly and full year forecasted earnings estimates for the periods ending June 30,...

View all Commentary and Analysis

BIIB Is For Buy-O-Gen
10:30AM ET 6/12/2019 Seeking Alpha

A Biotech-Friendly Event In An Unfriendly Healthcare Market
4:56PM ET 6/02/2019 Seeking Alpha

3 Gene Therapy Stocks For A Biotech Portfolio
12:53PM ET 5/20/2019 Seeking Alpha

Biotech News Recap: Biogen Reports Promising Data In ALS, Still Facing Several Challenges
4:29PM ET 5/05/2019 Seeking Alpha

Company Profile

Business DescriptionPacira Biosciences, Inc. operates as a holding company, which engages in the development, commercialization, and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ. View company web site for more details
Address5 Sylvan Way
Parsippany, New Jersey 07054
Phone+1.973.254.3560
Number of Employees518
Recent SEC Filing06/13/20194
Chairman, Chief Executive & Operating OfficerDavid M. Stack
Chief Financial OfficerCharles A. Reinhart
Vice President-Research & DevelopmentVladimir Kharitonov
Chief Medical OfficerRichard E. Scranton

Company Highlights

Price Open$43.92
Previous Close$44.08
52 Week Range$30.00 - 55.00
Market Capitalization$1.8 B
Shares Outstanding41.3 M
SectorHealth Technology
IndustryPharmaceuticals: Other
Next Earnings Announcement08/01/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings256.82
Earnings per Share$0.20
Beta vs. S&P 500N/A
Revenue$337.3 M
Net Profit Margin2.10%
Return on Equity2.40%

Analyst Ratings as of 06/07/2019

Buy
7
Overweight
0
Hold
8
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset